As I understand it, Tim Anderson of Sanford, Bernstein is letting his clients know that Dr. Kastelein -- yes, the PI from ENHANCE -- will be the discussant, at a recently-announced AHA Late Breaking session. The study? The mysterious Arbiter-6 HALTS, and presumably, the early termination of the same. Backgrounder on Arbiter HALTS-6 here.
From AHA's current agenda:
. . . .Late-Breaking Clinical Trials
LBCT.02.Late-Breaking Clinical Trials II.
Monday, Nov 16, 2009
West Hall D2
Monday, Nov 16, 2009, 11:07 AM -11:17 AM
ARBITER 6-HALTS: The Effect of Extended-release Niacin or Ezetimibe Added to Chronic Statin Therapy On Carotid Intima Media Thickness
Allen J. Taylor, Washington Hospital Center, Medstar Research Institute, Washington, DC; Todd C. Villines, Patrick J. Devine, Walter Reed Army Medical Center, Washington, DC; Mark Turco, Washington Adventist Hospital, Takoma Park, MD; Len Griffen, Cardiac Associates, Rockville, MD; Michael Miller, University of Maryland, Baltimore, MD; Eric J. Stanek, None, Thorofare, NJ; Neil J. Weissman, Washington Hospital Center, Medstar Research Institute, Washington, DC
Discussant:
John J. Kastelein,
Amsterdam, Netherlands. . . .
This should be interesting.
No comments:
Post a Comment